About: Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 November 2004

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в листопаді 2004 (uk) im November 2004 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 01 November 2004 (en) artículu científicu espublizáu en payares de 2004 (ast)
publication date	wds:Q57201691-2D5D7625-3C21-401A-8B4D-443D25BAD030
publication date	2004-11-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q57201691-004805A9-640B-4877-8A9C-DABA51D56435 wds:Q57201691-25CADEDD-8E8B-4AE7-B1F1-CF591CEB2D05 wds:Q57201691-29E9E4FA-2C4D-47C2-8144-DF57B0191FA8 wds:Q57201691-33BF1418-40CD-4704-B7FA-A4BB4BC15373 wds:Q57201691-3DFE90BD-907A-46CB-AD6E-C4CDAC4B7AEA wds:Q57201691-45B531D7-D184-4AD2-9C75-C86734BAAAB6 wds:Q57201691-4F7303F3-64AA-4940-8A17-3B08BC67E967 wds:Q57201691-5871A826-B7A1-4AA5-93D3-09E4032506F3 wds:Q57201691-88377B54-EECE-49B7-8DB6-6FD0E0CB0E3B wds:Q57201691-8AF7695E-EE59-44F7-9F01-58CBDDF07132 wds:Q57201691-8B50914B-8677-44E2-AA50-B43C4A7615D8 wds:Q57201691-A722DD55-EB9C-4B48-ADAC-3CDFA996916B wds:Q57201691-DBC1A679-64F2-48FF-91B7-CE5E1DBA006B wds:Q57201691-FBF6A6F8-A7ED-406D-998F-153740879872
author name string	R Repp M Kaufmann M Gramatzki M Bitzer A Ganser L Kanz J Hirsch P Brossart W Vogel K Fehnle W Brugger G Schlimok H-G Kopp F Grünebach
rdfs:label	Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study (en) Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study (nl)
skos:prefLabel	Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study (en) Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study (nl)
name	Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study (en) Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study (nl)
author	wds:Q57201691-4E7E4922-382A-4374-A042-0D794F691677
author	Markus G Manz
title	wds:Q57201691-72A00FDA-CECF-4FA8-B409-E9E3F012C12A
title	Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study (en)
page(s)	wds:Q57201691-1A138C91-9470-4A40-AAF0-2F92150380A2
page(s)	1691-1698
instance of	wds:Q57201691-4FAC6293-58E6-4FE9-9B48-A2F0A52E31BD
instance of	scholarly article
main subject	wds:Q57201691-22C1AC5B-2551-4AAD-84CB-94556660C48D wds:Q57201691-8FEAF7D9-692C-4E54-A53A-2A301F62C5EF wds:Q57201691-AB5F0095-2AFF-4035-82F5-2B14AD32CD2B wds:Q57201691-F9E5E2D9-4151-4F31-90A7-09C3D2D68AAE
main subject	chemotherapy mantle cell lymphoma rituximab stem cell transplantation
PubMed ID	wds:Q57201691-28E30E4F-B317-4C48-B141-622628672C00
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/15520073
PubMed ID	15520073
published in	wds:Q57201691-94D9FE20-2D4F-49A3-B98D-14EBFF48F265
published in	Annals of Oncology
issue	wds:Q57201691-34BD2893-E925-43FD-958F-CA34D04BD7B0
volume	wds:Q57201691-7C0590F3-5B5B-4CEE-BA45-A8A516F8DA34
issue	11
volume	15
DOI	wds:Q57201691-5ECA777D-4604-4726-A560-BA09E24D0657
DOI	http://dx.doi.org/10.1093/ANNONC/MDH425
DOI	10.1093/ANNONC/MDH425
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57201691
is cites work of	Clinical use of rituximab in haematological malignancies Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma Rituximab in hematopoietic cell transplantation Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group. Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation Stem cell transplantation for mantle cell lymphoma: if, when and how? Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms Advanced-stage III/IV follicular lymphoma: treatment strategies for individual patients Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma. The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma The prognostic significance of minimal residual disease in the early phases of chemotherapy in dogs with high-grade B-cell lymphoma Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software